For a decade, US cannabis operators could print profits and still sit outside the biggest pool of equity capital on earth. This week that started to change. Not with a legalization vote or a blowout earnings print, but with two index additions that force passive funds to own the names and put them on the radar of every manager benchmarked to those indices. The headlines look quiet. The capital structure consequences are not.
What Actually Happened
On Monday, Trulieve (NYSE: TRLV) announced it had been added to the S&P Total Market Index and the S&P Completion Index, along with their health care sub indices. On Wednesday, Curaleaf (TSX: CURA) said it had joined the FTSE Canada All Cap Index, its second major Canadian benchmark after entering the S&P/TSX Composite a year ago.
Neither headline will move a stock 20 percent in a day. Both change who is allowed to own it. In a sector that has spent a decade locked out of institutional portfolios, that is the whole game.
Why Passive Money Changes Everything
Roughly one third of US equity assets sit in passive vehicles that do not pick stocks. They buy whatever the index says to buy, in the weight the index says to hold it. A company outside every index is, for that pool of capital, invisible. It can be profitable, growing, and cheap, and the big index funds will still never own a share because the rulebook does not allow it.
Index inclusion flips that switch. Once a stock is in the S&P Completion Index, funds tracking it are obligated to buy at reconstitution, in proportion to float adjusted market cap. That creates a permanent bid that does not care about rescheduling rumors or 280E. It buys on inflows and sells on outflows, mechanically, every day. For stocks that have traded on retail sentiment and thin liquidity their entire lives, replacing a slice of that shareholder base with index money reduces volatility, tightens spreads, and lowers the cost of capital.
It also unlocks the active money downstream. Most institutional mandates are benchmarked. A portfolio manager cannot take a position in a name outside her benchmark universe without a compliance conversation. Once Trulieve is in the S&P Total Market Index, it is in the opportunity set for every US all cap and small cap manager measured against S&P.
The Playbook Is Now Public
Index inclusion is not something a company applies for. It is the mechanical output of meeting eligibility rules that, for US cannabis, were impossible to satisfy until this year.
Trulieve checked every box in sequence. It restructured to medical only under Schedule III, which eliminated the federal illegality problem that kept the NYSE’s door shut. It redomiciled to the United States, which cleared the domicile requirement. It listed on the NYSE in June. Three months later, S&P’s quarterly rebalance picked it up because the rules said it should. The April DEA rule made the medical only entity legally distinct from the adult use business. That was not an accident of timing. That was the plan.
Curaleaf’s route ran through Toronto. The TSX accepted its listing in 2023, the S&P/TSX Composite added it in September 2025, and the FTSE Canada All Cap followed this month. Same mechanics: exchange listing first, then eligibility, then a rules based provider adds you at the next review.
Who Is Next in Line
S&P was the first domino, not the last. The Russell reconstitution is the bigger prize. The Russell 2000 and 3000 are the dominant small cap benchmarks in the US, with far more passive money tracking them than the S&P Completion Index. FTSE Russell has moved to a semiannual schedule, so Trulieve’s next window comes later this year rather than next June. CRSP, the index family behind Vanguard’s Total Stock Market ETF, rebalances quarterly. Each one adds another layer of structural demand.
The rest of the sector now has a map:
- Green Thumb has said for years it would list on a US exchange the moment the rules permit. It is a British Columbia company, so domestication is required for S&P eligibility, and its adult use exposure likely means it needs the administrative law judge’s decision to extend Schedule III before the NYSE or Nasdaq will accept it.
- Verano did a 1 for 5 reverse split in June specifically to meet minimum share price requirements for a US listing application.
- Cresco disclosed one time costs for preparations for a potential US exchange listing in its last quarter.
- TerrAscend has been a TSX issuer since 2023 with the compliance infrastructure already built.
- Glass House is already on the NYSE alongside Trulieve, though as a Canadian domiciled issuer its path into US indices is more complicated.
The fork in the road is the one Trulieve chose: ring fence medical operations and list now, or wait for full rescheduling and list whole. If the judge recommends Schedule III for all cannabis and the DEA administrator adopts it, the exchanges will process a wave of applications in early 2027, and each listing triggers the same sequence Trulieve just completed.
The Operator Takeaway
Cannabis has spent years arguing it deserves institutional capital. Index inclusion is the mechanism by which that capital actually arrives. For operators, the message is blunt: clean governance, audited financials, and exchange ready compliance are now competitive advantages, not nice to haves. The companies that did the boring work early are the ones the index funds are buying. Watch the Russell window later this year. That is where the real money moves.
For more Curaleaf news, see Curaleaf Hello Farms and the 31.8M Sixth Circuit case. For another growth story, see Verano Virginia Texas 2027 growth and Archos.
FAQs
1. 1. What actually happened this week?
Trulieve joined the S&P Total Market Index and the S&P Completion Index, and Curaleaf joined the FTSE Canada All Cap Index. Two quiet headlines with major capital structure consequences.
2. 2. Why does index inclusion matter so much?
Roughly one third of US equity assets sit in passive vehicles that buy whatever the index holds. A company outside every index is invisible to that pool. Inclusion flips the switch and creates a permanent mechanical bid.
3. 3. How does this unlock active money too?
Most institutional mandates are benchmarked. Once Trulieve sits in the S&P Total Market Index, it enters the opportunity set for every US all cap and small cap manager measured against S&P.
4. 4. What playbook did Trulieve follow?
It restructured to medical only under Schedule III, redomiciled to the United States, listed on the NYSE in June and was picked up in the quarterly rebalance three months later. The April DEA rule made the medical entity legally distinct from adult use.
5. 5. Why is this cannabis’s capital markets milestone?
A decade of profitable operators sat outside the biggest equity pool on earth. Index inclusion is the mechanical proof that a compliant cannabis company can now clear the same gates as any other stock.
Source
Original analysis by The Dales Report (Baked In newsletter, no named byline on the source page): Why Trulieve & Curaleaf getting added to indices matters